BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study. Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their…